Hansa Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was SEK 67.08 million compared to SEK 4.95 million a year ago. Net loss was SEK 153.95 million compared to SEK 148.37 million a year ago. Basic loss per share from continuing operations was SEK 3.45 compared to SEK 3.34 a year ago. Diluted loss per share from continuing operations was SEK 3.45 compared to SEK 3.34 a year ago.
For the nine months, sales was SEK 123.76 million compared to SEK 18.48 million a year ago. Net loss was SEK 462.46 million compared to SEK 384.89 million a year ago. Basic loss per share from continuing operations was SEK 10.39 compared to SEK 8.65 a year ago. Diluted loss per share from continuing operations was SEK 10.39 compared to SEK 8.65 a year ago.